Browse the evidence

The efficacy of lifestyle interventions in clinical care for T2D is unclear.

Clinicians should be cautious in relying solely on lifestyle interventions without further evidence.

Exercise therapy is not utilized satisfactorily in the clinical treatment of T2D.

Healthcare providers should consider integrating structured exercise into T2D treatment plans more effectively.

Exclusive reductionism in nutritional science has contributed to confusion about a healthy diet and the development of chronic diseases worldwide.

Practitioners should consider the holistic view of nutrition rather than just focusing on nutrients.

A complementary holistic perspective is needed for effective communication about diet and health to prevent chronic diseases.

Health professionals should adopt a holistic approach in dietary recommendations.

Set structure (cluster-set vs. traditional-set) seems to be of less importance for changes in bench press velocity and power.

Practitioners may choose either set structure without concern for significant differences in outcomes.

No significant differences in overall time trial or inclined ride times were observed between intervention groups.

Creatine and carbohydrate loading may not affect overall time trial performance but can enhance specific sprint efforts.

Current guidelines provide limited recommendations for the medical management of patients with obesity-related HFpEF.

Healthcare providers may need to seek additional resources for managing obesity-related HFpEF.

The role of GLP-1 receptor agonists in obesity-related HFpEF remains unclear.

Further research is needed to clarify the role of GLP-1 receptor agonists in managing obesity-related HFpEF.

Low intuitive eating scores were associated with low binge-eating classification rates only if both dichotomous thinking and rigid restraint scores were low.

Practitioners should consider the interplay of multiple eating patterns when assessing binge eating risk.

Higher in vivo adipose cell turnover is positively associated with BMI and VAT/TAT.

Practitioners should consider the role of adipose cell turnover in assessing metabolic health in obese individuals.

Preadipocyte and adipocyte formation is negatively associated with insulin sensitivity.

This finding suggests that higher adipocyte formation may be detrimental to insulin sensitivity, which is crucial for metabolic health.

BAT does not mediate metabolic adaptation to overeating in humans.

BAT is not a factor in how the body adapts to overeating.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

A single-site measure of muscle shape does not adequately capture the effects of exercise training interventions.

Multiple measurement sites should be used to assess training effects accurately.

Low responders displayed higher plasma leptin levels compared with high responders at baseline.

Understanding leptin levels can help tailor interventions for different responder types.

Nineteen approved and pending Medicaid Section 1115 waivers address nutrition, with eleven submitted or approved since 2021.

Practitioners should be aware of the increasing number of waivers addressing nutrition in Medicaid.

There is no significant difference in muscle hypertrophy between segments in the placebo group.

Placebo may not be effective for muscle hypertrophy in resistance training contexts.

Magnitude of residual variation in weight was associated with all-cause mortality (relative risk, 1.25 for 1 U of additional variation; 95% CI, 1.06-1.47).

Practitioners should consider the impact of weight fluctuations on overall mortality risk.

Magnitude of residual variation in weight was associated with ischemic heart disease mortality (relative risk, 2.49; 95% CI, 1.41-4.38).

Weight management strategies should be carefully considered to reduce heart disease risk.

Weight loss interventions, if deemed to be necessary, should be considered carefully.

Practitioners should approach weight loss interventions with caution, considering potential risks.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

No significant effect of frequency was found for muscle hypertrophy.

Older adults may not experience additional muscle growth benefits from increasing resistance training frequency beyond two sessions per week.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

There was no difference in mean total body weight change between IBD and non-IBD cohorts after semaglutide initiation.

Weight loss outcomes with semaglutide appear consistent regardless of IBD status.